HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2520 Demcizumab (Anti-DLL4) Demcizumab (Anti-DLL4) is a monoclonal antibody taregting DLL4. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. MW: 145.5 KD. Aug 10 2023
A2521 Rovalpituzumab (Anti-DLL3) Rovalpituzumab (Anti-DLL3) is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). MW: 145.5 KD. Aug 10 2023
A2522 Anti-DKK1 Anti-DKK1 (BHQ880) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. Aug 10 2023
A2523 Ulocuplumab (Anti-CXCR4 / CD184) Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD. Aug 10 2023
A2524 Anti-CXCL8 / IL-8 Anti-CXCL8 / IL-8 (ABX-IL8) is a antibody targeting CXCL8. MW: 145.5 KD. Aug 10 2023
A2525 Eldelumab (Anti-CXCL10 / IP-10) Eldelumab (Anti-CXCL10 / IP-10) is a humanised monoclonal antibody (IgG1 type) targeting CXCL10. Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. MW: 145.5 KD. Aug 10 2023
A2526 Quetmolimab (Anti-CX3CL1 / Fractalkine) Quetmolimab (Anti-CX3CL1 / Fractalkine) is a humanized monoclonal antibody targeting CX3CL1. MW: 150 KD. Aug 10 2023
A2530 Anti-CSF3 / G-CSF Anti-CSF3 / G-CSF (CSL324) is an antibody targeting CSF3. It is useful for studying growth factor signaling. MW: 145.5 KD. Aug 10 2023
A2531 Anti-CSF2Rb / CD131 Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD. Aug 10 2023
A2532 Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD. Aug 10 2023
A2533 Otilimab (Anti-CSF2 / GM-CSF) Otilimab (GSK 3196165) is an humanized monoclonal antibody targeting GM-CSF (granulocyte-macrophage colony-stimulating factor). Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor. MW: 145.5 KD. Aug 10 2023
A2534 Lacnotuzumab (Anti-CSF1 / M-CSF) Lacnotuzumab (Anti-CSF1 / M-CSF) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1, that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis. MW: 150 KD. Aug 10 2023
A2535 Lampalizumab (Anti-Complement Factor D) Lampalizumab (Anti-Complement Factor D) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. MW: 145.5 KD. Aug 10 2023
A2536 Avdoralimab (Anti-Complement C5aR1) Avdoralimab (Anti-Complement C5aR1) is a fully human IgGκ monoclonal antibody targeting the complement C5a receptor 1 (C5aR1), that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research. MW: 145.5 KD. Aug 10 2023
A2537 Ravulizumab (Anti-Complement C5) Ravulizumab (Anti-Complement C5) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. MW: 145.5 KD. Aug 10 2023
A2538 Eculizumab (Anti-Complement C5) Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research. MW: 145.5 KD. Aug 10 2023
A2539 Tesidolumab (Anti-Complement C5) Tesidolumab (Anti-Complement C5) is a fully-human IgG1/λ monoclonal antibody targeting against Complement C5. Tesidolumab blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex. MW: 145.5 KD. Aug 10 2023
A2540 Anti-Complement C3 Anti-Complement C3 (NGM621) is an antibody targeting Complement C3. It binds with high affinity to intact human C3. It is used in the research for treatment of Geographic Atrophy. MW: 145.5 KD. Aug 10 2023
A2541 Anti-Clusterin Anti-Clusterin (AB-16B5) is a humanized IgG2 antibody targeted against clusterin. It is an inhibitor of the epithelial to mesenchymal transition. Anti-Clusterin (AB-16B5) can be used for cancer research. MW: 145.5 KD. Aug 10 2023
A2542 Tepoditamab (Anti-CLEC12A / CD371) Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD. Aug 10 2023